Increasing utilization of prostate magnetic resonance imaging for elevated PSA: A TriNetX analysis
BJUI Compass · 2026-11 · 7 (11)
DOI: 10.1002/bco2.70318 ↗At a glance
Journal article in BJUI Compass, published online on 2026-11-19. Written by Jack T. Peterson and 11 co-authors. 23 references. The full text is freely available (open access, CC BY 4.0). Funded by: Prostate Cancer Foundation, Robert H. Lurie Comprehensive Cancer Center, U.S. Department of Defense.
Abstract (original language)
Objective
This study aimed to evaluate contemporary prostate MRI utilization among biopsy‐naïve patients with elevated PSA and its association with subsequent prostate cancer (PCa) diagnosis. Patients and Methods We queried the TriNetX Research Network (2016–2025) for patients with elevated PSA (4–50 ng/mL) and no previous prostate biopsy or PCa diagnosis. Receipt of MRI or biopsy after first elevated PSA value was identified. Outcomes of interest among biopsied patients were (1) receipt of MRI prior to biopsy and (2) subsequent diagnosis of PCa. Overall cohort and propensity score matched analyses by race were conducted among biopsied patients. Sensitivity analyses expanded event windows from 6 to 12 months and evaluated a subgroup with confirmed second elevated PSA value.
Results
We identified 550 352 patients with 32 230 (5.9%) receiving prostate MRI within 6 months (2.6% in 2016 to 9.3% in 2025) and 33 017 (6.0%) undergoing prostate biopsy. Of MRI patients, 11 353 (35.2%) received biopsy within 6 months. Pre‐biopsy MRI use increased from 13.8% in 2016 to >50% by 2023 (52.7% in 2025). The estimated negative biopsy rate was lower for MRI versus Non‐MRI cohorts (29.9% vs. 45.3%). PCa diagnosis among biopsied patients increased by age (e.g., 47.9% for age 40–49, 70.4% for age 70–80). Black patients had lower MRI utilization prior to biopsy (e.g., Black 48.2% vs. White 54.8% in 2025), which was confirmed on PSA‐stratified propensity score matched analyses. Sensitivity analyses showed similar findings with ~30% receiving upfront MRI by 2025 in the repeat elevated PSA subgroup.
Conclusions
Prostate MRI utilization increased over time to >50% before biopsy with slower rise after 2023 but remains lower for Black patients across age and PSA strata. Many patients did not receive a biopsy after MRI although appropriateness of deferral is uncertain. Pre‐biopsy MRI was associated with lower negative biopsy rates.
Funding
- Prostate Cancer Foundation
- Robert H. Lurie Comprehensive Cancer Center
- U.S. Department of Defense
- National Institutes of Health
Cite
APA
Peterson, J. T., Agrawal, P., Fink, K., Huang, M. M., Su, Z. T., Handa, N., Alam, R., Miller, F. H., Bagci, U., Ross, A. E., Murphy, A. B., & Patel, H. D. (2026). Increasing utilization of prostate magnetic resonance imaging for elevated PSA: A TriNetX analysis. BJUI Compass, 7(11). https://doi.org/10.1002/bco2.70318
Vancouver
Peterson JT, Agrawal P, Fink K, Huang MM, Su ZT, Handa N, et al. Increasing utilization of prostate magnetic resonance imaging for elevated PSA: A TriNetX analysis. BJUI Compass. 2026;7(11). doi:10.1002/bco2.70318
BibTeX
@article{Peterson2026,
author = {Peterson, Jack T. and Agrawal, Pranjal and Fink, Kathryn and Huang, Mitchell M. and Su, Zhuo T. and Handa, Nicole and Alam, Ridwan and Miller, Frank H. and Bagci, Ulas and Ross, Ashley E. and Murphy, Adam B. and Patel, Hiten D.},
title = {Increasing utilization of prostate magnetic resonance imaging for elevated PSA: A TriNetX analysis},
journal = {BJUI Compass},
year = {2026},
volume = {7},
number = {11},
doi = {10.1002/bco2.70318}
}
EUVIMED